Voyager Therapeutics Inc - Asset Resilience Ratio
Voyager Therapeutics Inc (VYGR) has an Asset Resilience Ratio of 56.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Voyager Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Voyager Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Voyager Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VYGR market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $163.81 Million | 56.82% |
| Total Liquid Assets | $163.81 Million | 56.82% |
Asset Resilience Insights
- Very High Liquidity: Voyager Therapeutics Inc maintains exceptional liquid asset reserves at 56.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Voyager Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Voyager Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Voyager Therapeutics Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Voyager Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.69% | $195.32 Million | $393.05 Million | +3.55pp |
| 2023-12-31 | 46.14% | $162.07 Million | $351.28 Million | +33.66pp |
| 2022-12-31 | 12.48% | $19.89 Million | $159.36 Million | +4.69pp |
| 2021-12-31 | 7.79% | $15.11 Million | $193.85 Million | -21.53pp |
| 2020-12-31 | 29.32% | $76.70 Million | $261.58 Million | -25.78pp |
| 2019-12-31 | 55.11% | $195.49 Million | $354.76 Million | -6.44pp |
| 2018-12-31 | 61.54% | $108.95 Million | $177.03 Million | -13.01pp |
| 2017-12-31 | 74.55% | $137.52 Million | $184.48 Million | +1.87pp |
| 2016-12-31 | 72.68% | $137.78 Million | $189.57 Million | +1.63pp |
| 2015-12-31 | 71.05% | $163.03 Million | $229.46 Million | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more